As a result of the challenges presented with the COVID-19 public health emergency, the FDA is extending its policy which will give developers and potential sponsors an additional six months to engage with the FDA to meet premarket approval requirements.
Read more: FDA Extends Enforcement Discretion Policy for Certain Regenerative Medicine Products